The human CD34 surface antigen is selectively expressed on stemlprogenitor cells within the hematopoietic system. Because CD34 expression is tightly linked t o the immature status of hematopoietic cells, with expression being rapidly lost as hematopoietic cells mature and differentiate, an examination of its regulation may provide important insights into the molecular control of blood cell development. A eomparison of the CD34 nuclear transcription rate in CD34+ and CD34-cells indicated that the CD34 gene is transcriptionally regulated in hematopoietic cell lines. In a previous report, we had identified t w o major clusters of CD34 transcription initiation sites by 5' RACE (rapid amplification of cDNA ends) analysis. In transient transfection experiments, we now demonstrate the ability of sequences encompassing each of these clusters t o function as promoters of transcription in CD34' cells. These promoters functioned at equivalent lev-
els in CD34' and CD34-cells, and the addition of 5' flanking sequences, extending as far as 3.7 kb upstream, to the core promoters did not differentially modify the level of expression in CD34+ versus the CD34-cell lines. An examination of DNase I hypersensitivity sites within an l&kb segment of DNA, extending 9 kb either side of the proximal promoter, showed six sites that were primarily associated with CD34-expressing cells. Taken together, these data indicate that the CD34 promoter sequences alone do not confer tissueor stage-specific expression. Appropriate transcriptional regulation of the CD34 gene must be controlled by chromatin structure, as identified by DNase I hypersensitivity, and/or by other tissue-and stage-specific elements present outside of the promoter region. 0 7994 by The American Society of Hematology.
mouse genes to identify common features that may be important in transcriptional regulation of the genes. The strongest region of humadmouse homology occurred in exon 1 between positions +l00 and +200! We also identified three short regions of partial homology upstream of the 5' most transcription initiation site! We are interested in identifying the regulatory mechanisms that direct selective expression of CD34 to the earliest hematopoietic cells. The elucidation of stedprogenitor cellspecific regulatory DNA sequences and transcriptional regulatory proteins would likely provide insight into early hematopoiesis, as well as be of potential value in hematopoietic stem cell gene therapy. We have previously shown, using reverse transcription-polymerase chain reaction (RT-PCR) that CD34 mRNA is present in tumor cell lines expressing CD34 surface antigen, but not in the CD34-hematopoietic cell lines examined.' Similarly, CD34 mRNA was detectable by RT-PCR in a pool of as few as 50 CD34' bone marrow cells, but was undetectable in as many as 8,000 mature peripheral blood cells? To examine whether the human CD34 gene is primarily regulated at the transcriptional level, in this study we evaluated the CD34 nuclear transcription rate in nuclear run-on assays. Furthermore, we evaluated the ability of sequences spanning the transcription initiation sites to direct transient expression of the luciferase gene in two CD34' and four CD34-leukemic cell lines. Finally, we examined the chromatin structure of 5' flanking, exon 1 , and intron 1 sequences in CD34' versus CD34-cell lines by mapping DNase I hypersensitive (HS) sites.
[B-lymphoid; ATCC], Thp-l [monoblastic; ATCC], HeLa [cervical carcinoma; UCSF Cell Culture Facility], Ball-l [B-lymphoid; Institute of Medical and Veterinary Science, Adelaide, Australia]) were maintained according to recommended culture conditions. The presence or absence of CD34 antigen expression on leukemic cell lines was confirmed by fluorescence-activated cell sorter (FACS) analysis using the phycoerythrin-labeled anti-HPCA-2 monoclonal antibody (anti-CD34; Becton Dickinson, Mountain View, CA). A primary acute myeloid leukemia sample (AML,), stage M1, was typed 90% CD34+, a stage M2 AML (AML) 97% CD34+, an acute lymphocytic leukemia sample (ALL) 90% CD34+, and a stage M5 AML (AML,) 2% CD34'. Human peripheral blood T cells were prepared by elutriation of the Ficoll-Hypaque mononuclear fraction and depletion of B cells by nylon wool.
Nuclear run-on experiments. Nuclei (5 X 10' ) were prepared from cultured cell lines as previously described" and stored in liquid nitrogen until used. Reactions were initiated by adding 100 pL elongation buffer (20 Ci/mmol; Amersham, Arlington Heights, IL) to each of the nuclei preparations. Reactions were performed at 30°C for 30 minutes, terminated by the addition of 80 U RNase-free DNase, and incubated an additional 10 minutes at 30°C. RNAs were purified by phenol/ chloroform extraction, ethanol precipitation, and centrifugation through RNase-free G-50 Sephadex spin columns (Boehxinger Mannheim, Indianapolis, IN). Equal numbers of counts of nascent radiolabeled transcripts were hybridized to Nytran membranes containing 10 pg of each indicated uncut probe.. Hybridizations were performed for 24 hours at 42°C in 10 mmoVL Tris-HC1 (pH 7.6), 0.33 mmom NaCI, 10 mmoVL EDTA, 0.2% sodium dodecyl sulfate (SDS), 50 pg/mL tRNA, 50 pg/mL salmon sperm DNA, 0.05% sodium pyrophosphate, and 2 x Denhardt's solutions. Membranes were washed in 1 X SSC at room temperature for 30 minutes, followed by 0.2X S S U 0.1 % SDS at 65°C for 30 minutes. Autoradiography was performed at -70°C for 5 days with an intensifying screen. Densitomem measurement of the hybridizing bands was performed using a 300 A Computing Densitometer (Molecular Dynamics, Sunnyvale, CA).
Probes used for the nuclear run on studies included a 1.5-kb partial CD34 cDNA extending from exon 1 through the 5' end of exon 8 (~x Y 6 -2 )~; a 1.5-kb Sal I to EcoRI fragment containing CD34 upstream, exon 1, and intron 1 genomic DNA sequences ( P X Y~)~; 1.85 kb of human @-actin cDNA sequences (~lBpA-1)'~; 3.1 kb of cDNA sequences (Xho UNco I) encoding human c-myb (pGlpmybNX; kindly provided by N. Ni~olaides~'); and the pBluescript M13+ vector (Stratagene, La Jolla, CA). The p-actin cDNA sequences served as a positive control, and Bluescript vector sequences controlled for nonspecific background hybridization.
Detection of DNase I hypersensitive sites. Nuclei isolations and DNA digestions were performed essentially as previously described. 16 Briefly, nuclei were isolated from cells by lysis in nuclei isolation buffer (60 mmol/L KCI, 15 mmoVL NaCI, 5 mmoVL MgCI2, 10 mmoVL Tris, pH 7.4, 300 mmol/L sucrose, 0.1 mmol/L EGTA, 0.5 mmol/L phenylmethylsulfonyl fluoride [PMSF], 5 pg/ mL leupeptin, 10 pg/mL aprotinin, 0.1% Nonidet-P40) and resuspended to nucleic acid concentration of approximately 0.4 mg/mL. Aliquots of nuclei were digested for 3 minutes at 22°C with the indicated concentrations of DNase I (Worthington) in 60 mmol/L KCI, 15 mmoVL NaCI, 5 mmoVL MgClz, 10 mmoVL Tris, pH 7.4, 300 mmoVL sucrose, 1 mmoVL CaCI2. DNA was purified, digested with EcoRI or EamHI restriction enzymes, electrophoresed on a 0.8% agarose gel, blotted onto Hybond N membrane (Amersham), and hybridized to 3ZP-labeled CD34 gene fragments in Rapid-hyb buffer (Amersham) containing 0.25 mg/mL denatured herring DNA for 3 hours at 67°C. After hybridization, filters were washed in 0.1 X SSC, 0.1% SDS, 1 mmoVL sodium pyrophosphate at 67°C.
Plasmid constructions. Molecular cloning was performed using standard pro to col^.'^ The promoterless pGL-Basic vector (Promega, Madison, WI), containing the firefly luciferase gene, was used to create all rep0rte.r gene constructs. Identities of constructed plasmids were confirmed by restriction enzyme digestion, PCR amplification, and, in several instances, by partial DNA sequencing. For pGL( -1.1 kb/+302)A, a BamHYSac I fragment (-1.1 kb/+78) was excised from ADBl l9 and subcloned into pBluescript M13+ (Stratagene) to give pXY7. The Sma I (flanking BarnHI site)/Sac I fragment was transfered from pXY7 into the Sma YSac I sites of pGL-Basic to give rise to pGL(-l.l kb/+78). The Apa I site at +302 in P X Y~~ was converted into an Xho I site to generate pXY4'. The Sac UXho I fragment (+78/+302) from pXY4' was inserted into pGL(-I.l kb/+78) to generate pGL(-1.1 kb/+302). The CD34 translational initiation site (ATG at +272-274) within pGL(-1.1 kb/+302) was mutated to TAG, via multi overlapping PCR," to create pGL( -1.1 kb/+302)A. For pGL(-3.7 kb/+302)A, an EcoRl/Sac I fragment (-3.7 kb/+78) was excised from ADBl l9 and subcloned into pBluescript M13+ (Stratagene) to give pXY8. The EcoRVSac I fragment was then transfered from pXY8 into the Sma USac I sites of pGLBasic to give rise to pGL(-3.7 kb/+78), after filling in the EcoRI end with Klenow fragment (Promega). The Sac UXho I fragment from pGL(-1.1 kb/+302)A was inserted into pGL(-3.7 kb/+78) to yield pGL(-3.7 kb/+302)A. The construction of other luciferasecontaining plasmids (shown in Fig 2) was based on the plasmids described above, and used PCR amplification with designed primers or restriction enzyme digestion at conveniently located sites to achieve deletion of the indicated sequences.
Transient transfection assays. Plasmids used for transfection were grown in Escherichia coli strain JM109, and purified by alkaline lysis and banding two to three times in cesium chloride. Transient transfection assays were performed basically as described by Pahl et Culture cells were split 1 day before transfection. On the day of transfection, logarithmically growing cells were washed twice and resuspended at a density of 5 X lo7 cells/mL in their normal serum-containing tissue culture medium. Twenty micrograms of uncut plasmid DNA was incubated with 200 pL of cell suspension (lo7 cells) in a BioRad 0.4 cm gap electroporation cuvette at room temperature for 5 minutes. Electroporation was performed with the Gene Pulser apparatus (BioRad, Richmond, CA) at 960 pF. The selected voltage was 280 V for KG-l and U937 cells, 240 V for A3.01 cells, and 220 V for RPM1 8402 and HeLa cells. Electroporated cells were transfered to petri dishes containing culture medium (10 mL for cell lines grown in suspension, 4 mL for HeLa cells). Eight hours after electroporation, cells were collected, washed twice with phosphate-buffered saline, and lysed. Enzymatic assays measuring luciferase activity in cell lysates were performed using the Luciferase assay system (Promega) and the Model 20e luminometer (Turner Design, Sunnyvale, CA) as recommended by the suppliers. In each experiment, control luciferase-containing plasmids (pGLpromoter [containing the SV40 promoter; Promega], pGL-control [containing SV40 promoter and enhancer; Promega], pH@APIE [containing human @-actin promoter and enhancer; kindly provided by G . Sin, University of California at San Diego"]) and/or pGL(-213/+302)A were included to control for transfection efficiency. Similarly, pGL-Basic (containing only the luciferase gene without any promoter/enhancer elements; Promega) controlled for background luciferase expression. Expression levels for the various experimental constructs, when normalized to controls, were quite consistent from experiment to experiment.
RESULTS
The human CD34 gene is primarily regulated at the transcriptional level. In a previous report, we showed that MOLT-l3 KG-la U937 THP-1 A3.01 Raji CD34 RNA was detectable by RT-PCR in cells expressing the CD34 antigen (CD34' primary bone marrow cells; KG-1 and KG-la cell lines), but was absent in CD34 antigennegative cells (mature peripheral blood cells; U937, KS62, and A3.01 cell lines).9 To determine whether CD34 expression is regulated transcriptionally, the CD34 transcription rate was examined by nuclear run on assays in CD34' (Molt-13, KG-la) and CD34-(U937, Thp-l, A3.01, Raji) cell lines. Two CD34 target sequences were used in these studies: one containing 1.5 kb of cDNA sequences extending from exon 1 to 8, and another including 0.9 kb of exon I and intron 1 sequences.
As shown in Fig I , CD34 transcription was clearly detected in the CD34' KG-la and Molt-l3 cell lines. There was negligible CD34 transcription, using the CD34 exon 1-8 cDNA target sequences, in the CD34-cell lines examined. The level of CD34-specific hybridization, using these target sequences, was at least IO to 15 times lower in the CD34-cell lines than in the CD34' cell lines, as determined by laser densitometry. Reduced CD34 transcription in CD34-versus CD34' cell lines was evident when CD34-specific hybridization was compared with hybridization to either the Bluescript control or &actin sequences; the &actin control was included to facilitate comparison of transcription rates between different cell lines. These data indicate that CD34 expression in hematopoietic cell lines is largely regulated at the transcriptional level. It is perhaps significant that the level of signal from CD34 exon I/intron 1 sequences was non-negligible in CD34-cell lines, being approximately fivefold reduced with respect to the CD34' cell lines. Although these data still indicate transcriptional regulation of the CD34 gene, they raise the possibility that some initiation of transcription may occur in CD34-cells and that additional regulation at the level of transcriptional elongation may be required to explain the absence of CD34 transcription detectable by exon 1-8 sequences in CD34-cells.
Because of the presence of several potential myh-binding sites upstream of the CD34 gene, we considered the possibility that mvh, which is expressed at high level in CD34' cells," may contribute to CD34 gene expression. Figure 1 shows that human c-mvh is transcribed at a high level in CD34' and some CD34-cell lines. The absence of a clear correlation between the CD34 transcription rate and the cmyh transcription rate indicates that, if c-mvb protein is crucial to CD34 expression, its activation of CD34 must be regulated by the presence of additional regulatory proteins.
Sequences containing CD34 transcriptional initiation sires activate transcription in CD34' cells. In a prior report, we used 5' RACE (rapid amplification of cDNA ends) and RNase protection analysis to identify the CD34 mRNA start sites.' The 5' cDNA ends of individual 5'-RACE clones spanned 252 bp and could be segregated into an upstream and downstream cluster. While RNase protection analysis confirmed the existence of mRNAs initiating from within the upstream cluster, it did not unequivocally demonstrate transcripts initiating within the downstream cluster, perhaps because of the small length of the expected protected antisense RNA probe.
To demonstrate the functionality of these putative promoter sequences, we constructed expression plasmids containing various portions of the CD34 upstream and exon 1 sequences linked to the luciferase gene. These constructs are shown in Fig 2. Because of the possibility of CD34 transcription initiating from both upstream and downstream sites, most of our constructs included CD34 exon 1 sequences extending down to position +302. The CD34 ATG translation initiation site at +272 to +274 was mutated to eliminate translational initiation upstream of the luciferase gene; constructs containing this mutation are signified by A.
Transfection of constructs pGL(-3.7 kb/+302)A and pGL(-1.1 kb/+302)A into CD34' KG-l cells yielded a level of luciferase expression approximately threefold to sixfold above the pGL-Basic background control. Deletion of upstream sequences from -1. l kb to -516 increased transcriptional activity approximately fivefold, achieving an expression level 50% to 60% of the pGL-promoter control (containing the SV40 promoter sequences: data not shown). fect on promoter activity. Interestingly, further removal of sequences down to +78, deleting the upstream cluster of transcription initiation sites, still yielded promoter activity 60% of the pGL(-213/+302)A construct. These data showed that transcription may initiate outside of the upstream cluster, perhaps initiating within the downstream cluster of transcription initiation sites. A series of plasmids containing deletions at the 3' end of CD34 exon 1 sequences in the pGL(-213/+302)A construct were also constructed and assayed. Removal of 3' sequences to position +244 [represented by the construct pGL(-213/+244)A] had a minimal effect on promoter strength. Further deletion of 3' sequences to position +78 [pGL(-213/+78)] decreased promoter strength 75% to 80%. Sequences deleted in this construct contain the downstream cluster of transcription initiation sites, as well as l potential ets site, l potential myb site, and 2 potential Spl sites. ' To determine whether KG-1 transfection results were also representative of other CD34+ cell lines, constructs were also transfected into the CD34' RPMI 8402 cell line (Fig  1) . Transfection of constructs containing core promoter sequences (ie, sequences between -S 16 and +302) yielded a similar pattern of expression as obtained for KG-l cells. Expression was observed for both the pGL(-213/+78) construct (containing only the upstream transcription initiation sites [TISs]) and the pGL(+78/+302)A construct (containing only downstream TISs), consistent with our prior identification of multiple start sites for CD34 mRNAs. However, significant differences between RPMI 8402 and KG-1 cells were observed for constructs containing upstream sequences between -1.1 kb and -516. Addition of these sequences to the pGL(-5 16/+302)A construct decreased expression significantly (fivefold) in KG-l cells, whereas no such effect was observed in RPMI 8402 cells. These data suggest that there may be regulatory proteins in KG-l cells, but not RPMI 8402 cells, which interact with elements located between -S 16 and -l . 1 kb to downregulate transcription.
CD34 promoter sequences are also firnctional in CD34-cell lines. To determine whether the CD34 promoter sequences themselves confer cell-type specific andor stagespecific expression, we performed comparative transient expression assays in the CD34+ KG-l and RPMI 8402 cell lines, and the CD34-U937, A3.01, and HeLa cell lines. The results of these experiments are presented in Table 1 and Fig  3. In Table 1 , the activity of the core promoter pGL( -213/ +302)A is expressed, for each cell line, as a percentage of the activity of the &actin promoter/enhancer control (comesponding to a gene constitutively expressed in various cell types) or the SV40 early promoter control (also active in numerous cell types). The CD34 promoter sequences activated transcription in all CD34' and CD34-cell lines examined. When normalized with respect to the &actin promoter/ enhancer, pGL(-213/+302)A was expressed at approximately the same level in CD34+ and CD34-hematopoietic cell lines; we do not have a ready explanation for its increased expression relative to &actin promoter/enhancer in nonhematopoietic CD34-HeLa cells. Similarly, there was no clear difference for pGL(-213/+302)A expression in CD34' versus CD34-cell lines, when normalized with respect to the SV40 promoter. The net positive or negative contribution of upstream sequences was qualitatively similar in the CD34+ and CD34-cell lines examined (Fig 3) ; the only exception was for sequences between -1 .l kb and -516 in the CD34+ KG-l and RPMI 8402 cell lines, as previously noted. For example, the addition of sequences +78/+302 to the pGL(-213/+78) conctruct increased expression in all cell lines, although the magnitude of the increase varied. Constructs pGL(-2 I3/+78) and pGL(+78/ +302)A individually activated expression in both CD34 ' and CD34-cell lines. These data, therefore, did not show any differential ability of the upstream and downstream clusters of TlSs to function in CD34' versus CD34 cell lines.
Taken together, these data indicate that the regulatory elements contained within this region are not sufficient, in transient expression assays, to regulate the differential expression of CD34 in CD34' and CD34-cells. These results indicate that appropriate regulation must either be provided by regulatory mechanisms acting at the chromatin level, by additional DNA sequences, or by both. S 1 1 c~. i j i c UNuse I US sites urt' ~lniquely ussociuted with CD34 expression. The structure of chromatin in the vicinity of a given gene is known to play a significant role in governing its correctly regulated expression." DNase 1 HS sites within chromatin often correspond to sequences which play a critical role in activating transcription of the gene (eg, promoter, enhancer, locus control region
We have examined 9 kb of CD34 S' flanking sequences and 9 trations and most of the data used to produce the summaries in Fig 4A and Table 2 is shown in Fig 4B. To aid direct comparisons between cell types and to increase the resolution of the analyses, single representative DNase 1 digests of several of the above cell types are also displayed in Fig  S , which depicts a longer agarose gel in which the upper bands are clearly separated. By probing from either an EcoR1 site 3.7 kb upstream or a BurnHI site 1.1 kb upstream of the CD34 gene, a total of six DNase 1 HS sites were detected in each of the four CD34' cell types. Sites 1 through III were located I .7, 1.2, and 0.6 kb, respectively, upstream o f the gene. Site IV encompassed the Sac I site at position +78, between the two previously mapped transcription initiation sites. This site lies within the region required for maximum activity (-213 to +302) and most likely corresponds to the promoter. Sites V and VI were 3.6 and 7.2 kb, respectively, downstream of the first initiation site, within intron 1. With the exception of site IV, which was present as a weak site in Jurkat cells, sites 1 through IV were largely restricted to the CD34-expressing cells. Although sites V and VI were also absent in most of the CD34-cells, sites V and VI were prominent in U937 cells and site VI was present in Jurkat cells. Sites 11 through VI appeared with roughly similar kinetics, whereas site I was a relatively weak site appearing after more extensive DNase I digestion. We confirmed that appropriate DNase I digestions had been performed for each cell type, because ubiquitous DNase I HS sites in the interleukin-3 locus were readily detected for each series of digests (data not shown). N o additional DNase I HS sites were detected within the B~J~z H I fragment located 2.7 to 9 kb upstream of the gene (Fig 4A, data not shown) . These data show significant differences in the chromatin of CD34 expressing and nonexpressing cells. The enhanced presence of DNase I HS sites I to IV in cells expressing CD34 suggests that the upstream region contributes to the specific regulation of CD34 expression. Furthermore, these data may help resolve the discrepancy between the ability of transiently transfected CD34 promoter sequences to function in CD34-cells, and the inability of the equivalent endogenous sequences to function within the chromatin of the same cells.
DISCUSSION
The decrease in CD34 expression, which occurs upon differentiation of hematopoietic stedprogenitor cells, could, in principle, be regulated at the transcriptional level, the posttranscriptional level, or both. The nuclear run on data presented in this report strongly suggest that regulation of CD34 expression is primarily exercised at the transcriptional level. These data are consistent with our previous inability to detect CD34 RNA in CD34-primary or tumor cells, using In transient expression assays, we showed the ability of sequences encompassing the previously identified transcription initiation sites to activate reporter gene expression in CD34' cell lines. The expression of both the pGL(-213/ +78) construct (containing only the upstream TISs) and pGL(+78/+302)A construct (containing only downstream TISs) is consistent with our prior identification of multiple start sites for CD34 mRNA. We do not yet have information regarding the specific DNA sequences and DNA binding proteins responsible for activating CD34 transcription in CD34' cells. However, the significant activity of the pGL(+78/302)A construct, together with the similar activities demonstrated by the pGL(-213/+244) and pGL(-213/ +302)A constructs in KG-l cells, highlight the importance of sequences between +78 and +244. The suggested importance of this region is consistent with these sequences being the most homologous between human and mouse of upstream and exon 1 regions.' Although other previously identified humadmouse homologous sequences and myb/ets motifs in upstream CD34 sequences may yet prove to contribute to the activity of pGL(-516/+302)A and pGL(-213/ +302)A constructs, they do not appear to differentially regulate CD34 expression in CD34' versus CD34-cell lines, at least as measured in transient expression assays. Either these homology regions and myb/ets motifs play no role in differential CD34 gene regulation, or they only function in the context of chromatin.
Our transient expression experiments indicate that the core CD34 promoter is neither cell type-nor stage-specific, being able to function at approximately equivalent levels in a variety of CD34+ and CD34-cell lines. It is conceivable that the ability of CD34 promoter sequences to function transiently in CD34-cell lines is related to transcriptional initiation observed in CD34-cells (eg, exon l/intron 1 results in Fig l) . However, the transfection experiments did not show even the fivefold transcriptional initiation specificity in CD34+ versus CD34-cells suggested by the nuclear run-on experiments. The relative contribution of various promoter proximal sequences to transcriptional activity was quite similar in the CD34+ and CD34-cell lines examined. Taken together, these data indicate that the regulatory elements contained within this region (extending as far as -3.7 kb upstream), although apparently necessary for CD34 expression, are not sufficient to regulate the differential expression of CD34 in CD34' and CD34-cells. These results indicate that appropriate regulation must either be provided by additional cell type-specific enhancer sequences, by regulatory mechanisms acting at the chromatin level, or by both. Examples of nonspecific promoters being regulated in a tissue-specific manner by chromatin structure involving DNase I HS sites are the human and mouse Thy-l genes.28329
Bum et al" recently reported preferential expression of a CD34 promoter construct (extending upstream to -4.5 kb) in CD34' RPMI 8402 versus CD34-HeLa cells. We have not observed any specificity with sequences extending up to -3.7 kb, possibly suggesting a regulatory role for sequences between -3.7 and -4.5 kb. However, they observed no specificity in comparing its activity in RPMI 8402 versus CD34-U937 cells, even though U937 cells exhibit little or no CD34 nuclear transcription (our results and those of Bum et a124). Furthermore, our observed difference between the activity of promoter proximal sequences (ie, sequences between -1.1 kb and -516) in CD34+ KG-l versus CD34+ RPMI 8402 cell lines suggests caution in extrapolating results obtained with a single CD34' cell line. Such differences in the activity of specific DNA sequences between CD34+ cell lines suggest that certain features may reflect transforming events responsible for the leukemic transformation. Bum et aIz4 also reported selective demethylation in CD34+ cells of CpG islands at the 5' end of the CD34 gene. This result is consistent with transcriptional regulation of the CD34 gene, and identifies methylation as one possible mechanism of CD34 transcriptional control.
The identification of DNase I HS sites selectively present in CD34+ versus CD34-cells indicates an altered chromatin structure surrounding the CD34 gene in CD34+ cells, with selective hypersensitivity of certain sequences to DNase I cleavage. These data also perhaps resolve the discrepancy between the ability of CD34 promoter sequences to function transiently in CD34-cell lines, contrasted with their inability to function when present in chromatin of the same cell lines. If the CD34 sequences in normal chromatin of CD34-cells are present in a closed, inactive state, then they will be unable to respond to the same factors that facilitate their activity in transient assays. Although we have yet to demonstrate the particular function of sequences present at each of these DNase I sites, it is very possible that some of these sequences play a critical role in regulating CD34 transcription by binding specific protein factors. Site IV, located at or near the sites of transcriptional initiation, most likely identifies the CD34 promoter. Its near complete selective presence in CD34+ cells is consistent with the promoter only being active in CD34' cells. Bum et a124 also reported identification of a CD34-specific HS site at the promoter, but did not detect any CD34-specific HS sites corresponding to our sites I, 11, and 111. We do not know the reason for this difference.
DNase I HS sites I, 11, I11 and IV [when present in the (-1.1 kb/+302)A or (-3.7 kb/+302)A constructs] did not confer differential transient expression in CD34' versus CD34-cells. It is possible that sites I, 11, 111, and/or IV identify sequences that only function in a stage-specific manner when integrated into a normal chromatin configuration. DNase I HS sequences, whose activity is restricted to integrated chromatin, have been identified in the globin gene locus control region (LCR). Globin LCR sequences confer position independent and copy number dependent expression of linked genes when introduced into the germline of transgenic Only one of the four LCR DNase I HS sites individually functions as an enhancer in transient expression assays, with the other three HS sites only demonstrating function upon incorporation into chromatin. It is possible that similar behavior will be demonstrated by HS sites I, 11, or 111. May et a134 recently reported a cluster of three DNase I HS sites upstream of the mouse CD34 gene. It remains to be seen whether these are the mouse equivalents of human HS sites I, 11, and 111. We also identified two DNase I HS sites in intron 1. HS sites V and VI show some selectivity for CD34+ cells, although we did identify some CD34-cell lines in which these HS sites are present. In the transient expression experiments of Bum et al,24 sequences containing these sites did not activate transcription of the CD34 promoter in CD34+ RPMI 8402 cells. It is again possible that these sites may require presence in normal chromatin to be functional. Bum et alZ4 have recently reported a DNase I HS site at the extreme 3' end of the human CD34 gene, outside of the region examined in our experiments. This site activated transient expression in CD34+ RPMI 8402 cells, but not in CD34-HeLa or U937 cells. As such, it represents a potential cell-type specific enhancer for CD34 gene expression. Because the promoter proximal sequences do not confer cell type-or stage-specific expression in transient expression assays, appropriate regulation must either be provided by additional DNA sequences (eg, the 3' HS site identified by Bum et a124), by regulatory mechanisms acting at the chromatin level, or by both.
